Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) traded down 0.6% during mid-day trading on Monday . The stock traded as low as $64.70 and last traded at $64.70. 1 shares changed hands during trading, The stock had previously closed at $65.10.
Basilea Pharmaceutica Stock Down 0.6%
The firm’s fifty day simple moving average is $61.43 and its 200 day simple moving average is $67.04. The company has a quick ratio of 4.68, a current ratio of 5.11 and a debt-to-equity ratio of 0.59.
About Basilea Pharmaceutica
Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.
Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.
Further Reading
- Five stocks we like better than Basilea Pharmaceutica
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
